Accordingly, the enrolled patients represent a challenging to treat patient population with limited current
treatment options.
These Trial Patients had already exhausted all standard of care ,,, Their disease was heavily progressed... and from that perspective results are brilliant to date... NZT
Ann: TACTI-002 2nd line lung cancer data presented at 2022 WCLC, page-2
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
0.010(2.27%) |
Mkt cap ! $534.9M | |||
| Open | High | Low | Value | Volume |
| 44.5¢ | 45.5¢ | 43.0¢ | $944.4K | 2.126M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 18198 | 43.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.5¢ | 12500 | 1 |
View Market Depth
| Last trade - 16.10pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
44.0¢ |
Change
0.010 ( 0.80 %) |
||||
| Open | High | Low | Volume | ||
| 43.5¢ | 45.0¢ | 43.0¢ | 184791 | ||
| Last updated 15.58pm 31/05/2024 ? | |||||
| IMM (ASX) Chart |